Cancer Clinical Trials

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• We currently have no open studies for this disease site.

Contact Breast Research Coordinators at (605)322-3295 or email breastresearch@avera.org for more information.

• 201209135: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer
• Takeda X31025: A Phase 1 Evaluation of the Safety and Tolerability of TAK-128 in Combination with TAK-117 and Paclitaxel in Advanced Solid Tumors
• Tesaro TNE001: A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination with Everolimus in Advanced Ovarian and Breast Cancer
• NSABP B-59/GBG 96-Gepardouze: A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo (Immunotherapy)
• Intraoperative Radiation Therapy (IORT) Registry
• S1418/BR006: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy (Immunotherapy)
• OSU-16106/Bazan: Multi-Institution Phase II Trial of Intraoperative Electron Beam Radiotherapy Boost at the Time of Breast Conserving Surgery with Oncoplastic Reconstruction in Women with Early-Stage Breast Cancer
• C3441020: A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study of Talazoparib for Neoadjuvant Treatment of Germline BRCA 1/2 Mutation Patients with Early Triple-Negative Breast Cancer
• NSABP FB-13: An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer
• NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer (Immunotherapy)
• NRG-BR005: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
• NSABP FB-14: A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple-Negative Breast Cancer

Contact Research Coordinators at (605)322-3086 or (605)322-3295 or (605)322-3018 or (605)322-3295 for more information.

• BCCR: Development and Implementation of the Breast Cancer Collaborative Registry
• Single Fraction: Lumpectomy followed by intraoperative electron radiation therapy (IOERT) as a single dose of radiation therapy in early stage, node negative, invasive breast cancer

• NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Study is for Patients who have persistent unexplained low blood counts, circulating peripheral blasts, or have been recently diagnosed with MDS in the last 6 months and have not received treatment

• TCCR: Thyroid Tumor and Cancer Collaborative Registry (TCCR)

Contact Research Coordinators at (605)322-3221 or (605)322-3291 for more information.

• We currently have no open studies.

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
• A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) [Immunotherapy]
• NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Contact Research Coordinators at (605)322-3228 or (605)322-3291 for more information.

• SWOG S1400: Squamous Cell Lung Cancer

• Takeda X31025: A Phase 1 Evaluation of the Safety and Tolerability of TAK-128 in Combination with TAK-117 and Paclitaxel in Advanced Solid Tumors

• LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers

Contact Research Coordinators at (605)322-7536 or email gynresearch@avera.org for more information.

• GOG 0263: Stage I/IIA Cervical Cancer
• GOG 0264: Sex Cord-Stromal Tumors of the Ovary
• GSB: Gynecologic Specimen Bank for Genetic and Genomic Investigation
• Takeda X31025: A Phase 1 Evaluation of the Safety and Tolerability of TAK-128 in Combination with TAK-117 and Paclitaxel in Advanced Solid Tumors
• Tesaro TNE001: A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination with Everolimus in Advanced Ovarian and Breast Cancer
• CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy) [Immunotherapy]
• NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer(Immunotherapy) - Temporarily closed 09-May-2019
• 3000-03-005/ENGot-OV44: The FIRST: A randomized, Double-Blind, Phase 3 comparison of platinum-based therapy with TSR 042 and niraparib versus standard of care platinum-based therapy as First line treatment of stage III or IV nonmucinous Epithelial ovarian cancer (Immunotherapy)
• NRG-GY016: A Phase II Study of MK-3475 (Pembrolizumab) + Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary (Immunotherapy)
• NRG-GY014: A Phase II Study of Tazemetostat (EPZ-6438)(IND# 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
• NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• EA3132: Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
• NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• We currently have no open studies for this disease site.

Contact Research Coordinators at (605)322-3086 or (605)322-3291 for more information.

• EA5142 Anvil: Nivolumab after surgery and chemotherapy in treating patients with stage IB-IIIA non-small cell lung cancer
• CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
• NSABP B-59/GBG 96-Gepardouze: A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
• WIN001: Survival Prolongation by Rationale INnovative Genomics (SPRING): A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination
• NRG-GY016: A Phase II Study of MK-3475 Pembrolizumab+Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary
• A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)
• 3000-03-005/ENGot-OV44: The FIRST: A randomized, Double-Blind, Phase 3 comparison of platinum-based therapy with TSR 042 and niraparib versus standard of care platinum-based therapy as First line treatment of stage III or IV nonmucinous Epithelial ovarian cancer
• A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
• NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian
• S1418/BR006: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
• NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
• EA6134: Advanced BRAFV600 Mutant Melanoma

Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.

• We currently have no open studies for this disease site.

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• Alchemist: Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery

• EA5142 Anvil: Nivolumab after surgery and chemotherapy in treating patients with stage IB-IIIA non-small cell lung cancer (Immunotherapy)

• S1400: Phase II/III Biomarker-Driven Master Protocol
  for Second Line Therapy of Squamous Cell Lung Cancer
• WIN001: Survival Prolongation by Rationale INnovative Genomics (SPRING): A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination (Immunotherapy)
• D9108C00001: A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST)
• D9106C00001: A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
• D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.

• UTX-TGR-205: Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• EA6134: Advanced BRAFV600 Mutant Melanoma (Immunotherapy)

Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.

• Takeda C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen
• M13-367: A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma
• 54767414MMY2040: A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens

Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.

• We currently have no open studies for this disease site.

Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.

• ACE-536-MF-001: A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia with and without Red Blood Cell-Transfusion Dependence
  
• FEDR-MF-001: A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects with DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia VeraMyelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib (The “FREEDOM” trial)

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• We currently have no open studies for this disease site.

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• We currently have no open studies for this disease site.

Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.

• A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation (Immunotherapy)

Contact Research Coordinator at (605)322-3016 for more information.

• Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors